BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36827971)

  • 1. The impact of coding germline variants on contralateral breast cancer risk and survival.
    Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
    Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
    ; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
    JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    ; Dorling L; Carvalho S; Allen J; González-Neira A; Luccarini C; Wahlström C; Pooley KA; Parsons MT; Fortuno C; Wang Q; Bolla MK; Dennis J; Keeman R; Alonso MR; Álvarez N; Herraez B; Fernandez V; Núñez-Torres R; Osorio A; Valcich J; Li M; Törngren T; Harrington PA; Baynes C; Conroy DM; Decker B; Fachal L; Mavaddat N; Ahearn T; Aittomäki K; Antonenkova NN; Arnold N; Arveux P; Ausems MGEM; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Białkowska K; Blomqvist C; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Bonanni B; Børresen-Dale AL; Brauch H; Bremer M; Briceno I; Brüning T; Burwinkel B; Cameron DA; Camp NJ; Campbell A; Carracedo A; Castelao JE; Cessna MH; Chanock SJ; Christiansen H; Collée JM; Cordina-Duverger E; Cornelissen S; Czene K; Dörk T; Ekici AB; Engel C; Eriksson M; Fasching PA; Figueroa J; Flyger H; Försti A; Gabrielson M; Gago-Dominguez M; Georgoulias V; Gil F; Giles GG; Glendon G; Garcia EBG; Alnæs GIG; Guénel P; Hadjisavvas A; Haeberle L; Hahnen E; Hall P; Hamann U; Harkness EF; Hartikainen JM; Hartman M; He W; Heemskerk-Gerritsen BAM; Hillemanns P; Hogervorst FBL; Hollestelle A; Ho WK; Hooning MJ; Howell A; Humphreys K; Idris F; Jakubowska A; Jung A; Kapoor PM; Kerin MJ; Khusnutdinova E; Kim SW; Ko YD; Kosma VM; Kristensen VN; Kyriacou K; Lakeman IMM; Lee JW; Lee MH; Li J; Lindblom A; Lo WY; Loizidou MA; Lophatananon A; Lubiński J; MacInnis RJ; Madsen MJ; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Martinez ME; Maurer T; Mavroudis D; McLean C; Meindl A; Mensenkamp AR; Michailidou K; Miller N; Mohd Taib NA; Muir K; Mulligan AM; Nevanlinna H; Newman WG; Nordestgaard BG; Ng PS; Oosterwijk JC; Park SK; Park-Simon TW; Perez JIA; Peterlongo P; Porteous DJ; Prajzendanc K; Prokofyeva D; Radice P; Rashid MU; Rhenius V; Rookus MA; Rüdiger T; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Schürmann P; Shah M; Sohn C; Southey MC; Surowy H; Suvanto M; Thanasitthichai S; Tomlinson I; Torres D; Truong T; Tzardi M; Valova Y; van Asperen CJ; Van Dam RM; van den Ouweland AMW; van der Kolk LE; van Veen EM; Wendt C; Williams JA; Yang XR; Yoon SY; Zamora MP; Evans DG; de la Hoya M; Simard J; Antoniou AC; Borg Å; Andrulis IL; Chang-Claude J; García-Closas M; Chenevix-Trench G; Milne RL; Pharoah PDP; Schmidt MK; Spurdle AB; Vreeswijk MPG; Benitez J; Dunning AM; Kvist A; Teo SH; Devilee P; Easton DF
    N Engl J Med; 2021 Feb; 384(5):428-439. PubMed ID: 33471991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline breast cancer susceptibility genes, tumor characteristics, and survival.
    Ho PJ; Khng AJ; Loh HW; Ho WK; Yip CH; Mohd-Taib NA; Tan VKM; Tan BK; Tan SM; Tan EY; Lim SH; Jamaris S; Sim Y; Wong FY; Ngeow J; Lim EH; Tai MC; Wijaya EA; Lee SC; Chan CW; Buhari SA; Chan PMY; Chen JJC; Seah JCM; Lee WP; Mok CW; Lim GH; Woo E; Kim SW; Lee JW; Lee MH; Park SK; Dunning AM; Easton DF; Schmidt MK; Teo SH; Li J; Hartman M
    Genome Med; 2021 Dec; 13(1):185. PubMed ID: 34857041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
    J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating breast cancer predisposition genes in women of African ancestry.
    Díaz-Zabala H; Guo X; Ping J; Wen W; Shu XO; Long J; Lipworth L; Li B; Fadden MK; Pal T; Blot WJ; Cai Q; Haiman CA; Palmer JR; Sanderson M; Zheng W
    Genet Med; 2022 Jul; 24(7):1468-1475. PubMed ID: 35396981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
    Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
    Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of Genetic Alterations Associated With Interval Breast Cancer.
    Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
    JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of Pathogenic Germline Variants in
    Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.